United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at JPMorgan NAPA Valley Forum (Virtual) Transcript

Mar 31, 2021 / 04:00PM GMT
Release Date Price: €141 (-2.08%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Okay. Great. Good afternoon, everyone. My name is Jessica Fye. I'm the senior biotech analyst at JPMorgan. And we're continuing the Virtual Napa Valley Biotech Forum with United Therapeutic. I'm joined by the company's Chief Medical Officer, Dr. Gil Golden, and I think this is his first time in front of investors in a venue like this. So I think it's going to be great to get some more insight into the kind of medical point of view on the business. I also want to remind you guys to use the ask a question button on your screen to send me questions, there's a little lag, so just keep them coming, and we'll get to those.

Before we get started, I do want to pass it over to Dewey Steadman from IR to cover some of the legal logistics.

Dewey Steadman
United Therapeutics Corporation - Head of IR

Good afternoon, everyone. Today's presentation may include forward-looking statements. And we encourage you to visit our SEC filings for the latest risks and uncertainties related to those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot